Muira puama is the Viagra of the herbal world. It has a long history as aBrazilian folk remedy for impotence and clinical trials support this exotic
Supplement Facts
plant's role as a sexual stimulant. Furthermore, European and Brazilianphysicians have used muira puama to successfully treat menstrual
cramps, premenstrual syndrome, rheumatism, stress, dysentery, central
Amount Per Serving
nervous system disorders, and to alleviate depression. Because proper
Muira Puama (ptychopetalum olacoides)
hand, foot, and eye coordination are integral components of any athletic
endeavor, athletes also have used this central nervous system stimulant to
*Daily Value not established Herbal Benefits
Also called potency wood, this rainforest-derived plant is a bush or smalltree that can grow up to five meters in height in its native Brazilian Amazon. Brazilian tribes use a tea made from the bark and roots to treat impotence,neuromuscular conditions, rheumatism, cardiac asthenia (cardiovascular
weakness), gastrointestinal conditions and to prevent baldness. Observingthese traditional uses for muira puama led researchers to begin studyingits medicinal benefits in 1925, when one of the first pharmacological stud-ies on the herb was published. The study indicated that muira puama is
1. Murray MT. The Healing Power of Herbs. Prima Publishing. 1995.
effective in treating nervous system disorders, long standing neuralgias,
2. Dias Da Silva, R. Medicinal plants of Brazil. Botanical and pharmacognos-
chronic rheumatism, partial paralysis, and sexual impotence. At roughly
tic studies. Muira puama. Rev Bras Med Pharm. 1925; 1(1):37-41.
the same time, other physiological and therapeutic studies conducted by a
3. Penna M. Notas Sobre Plantas Brasileriras. Araujo Penn & Cia. Rio de
French researcher came to similar conclusions about muira puama's effec-
4. Waynberg J. Contributions to the Clinical Validation of the Traditional Use
of Ptychopetalum guyanna. Presented at the First International Congress
Amazon Aphrodisiac
on Ethnopharmacology, Strasbourg, France, June 5 - 9, 1990.
5. Werbach MR, Murray M. Botanical Influences on Illness, A Sourcebook of
Since muira puama was first introduced to Europeans, physicians in
clinical research. Third Line Press, Tarzana, California. 1994, p 200.
England and Germany have successfully treated impotent patients with it. The British Herbal Pharmacopoeia, published by the British Herbal
6. Susset JG, Tessier CD, Wincze J, Bansal S, Malhotra C, Schwacha MG.
Medicine Association, recommends muira puama for sexual dysfunction
Effect of yohimbine hydrochloride on erectile impotence: a double-blind
7. Waynberg J. Male Sexual Asthenia - Interest in a Traditional Plant-
Derived Medication. Ethnopharmacology, March 1995.
Dr. Jacques Waynberg and fellow researchers at the Institute of Sexologyin Paris, France, confirmed muira puama's aphrodisiac abilities in twohuman trials. In one study, 262 male patients suffering from lack of sexualdesire and the inability to have or maintain an erection experienced signif-icant improvement after taking 1 to 1.5 grams of muira puama extract dailyfor two weeks. Sixty-two percent of the patients suffering from diminishedlibido reported that muira puama extract had a dynamic effect and 51% ofthe impotent patients noticed an improvement after muira puama supple-mentation. Muira puama was more effective in treating erectile failure thanthe pre-Viagra alternative, yohimbine hydrochloride. In another study,Waynberg and colleagues investigated muira puama's psychologicaleffects on 100 impotent men. The researchers discovered that this Amazonherb did exert positive psychological benefits in these men.
Information contained in this Product Technical Sheet is for educational purposes only and is not intended to provide personal medical advice.
Such advice should be obtained from a medical professional. Reproduction of any part of this work is prohibited.
2003 Complementary Prescriptions™, a division of Vitamin Research Products, Inc.
Acyclovir Lauriad®: succès de l’essai de phase III Objectifs principal et secondaires atteints - Résultats finaux Paris, le 10 décembre 2009 – BioAlliance Pharma SA (Euronext Paris - BIO), société dédiée au traitement du cancer et du SIDA et aux soins de support, annonce aujourd’hui les résultats définitifs de son essai clinique pivot de phase III dans l’herpès lab